Banqladesh Drug Policy
Executive Summary
Monograph on "Public Health and Economic Dimensions of the New Drug Policy of Bangladesh" published by PMA. The monograph was written by Sri Lankan attorney, D.C. Jayasuriya. In a personal communication with govt. officials cited in the monograph, Jayasuriya estimates that Bangladesh's foreign currency expenditures on drug raw materials may have increased 40% between 1982 and 1983 as a result of the effort to increase local manufacturing.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.